nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—kidney cancer—sarcoma	0.33	1	CtDrD
Sunitinib—FLT1—sarcoma	0.0878	0.26	CbGaD
Sunitinib—PDGFRB—sarcoma	0.0726	0.215	CbGaD
Sunitinib—PDGFRA—sarcoma	0.0708	0.209	CbGaD
Sunitinib—KDR—sarcoma	0.055	0.163	CbGaD
Sunitinib—KIT—sarcoma	0.0519	0.154	CbGaD
Sunitinib—ABCG2—Dactinomycin—sarcoma	0.00924	0.111	CbGbCtD
Sunitinib—ABCG2—Mitoxantrone—sarcoma	0.00827	0.0996	CbGbCtD
Sunitinib—ABCC2—Vincristine—sarcoma	0.00629	0.0758	CbGbCtD
Sunitinib—ABCC2—Etoposide—sarcoma	0.00577	0.0695	CbGbCtD
Sunitinib—ABCG2—Vincristine—sarcoma	0.00569	0.0685	CbGbCtD
Sunitinib—ABCG2—Etoposide—sarcoma	0.00521	0.0628	CbGbCtD
Sunitinib—CYP3A7—Vincristine—sarcoma	0.0042	0.0506	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Vincristine—sarcoma	0.0042	0.0506	CbGbCtD
Sunitinib—CYP3A4—Thiotepa—sarcoma	0.00415	0.05	CbGbCtD
Sunitinib—ABCC2—Doxorubicin—sarcoma	0.00393	0.0474	CbGbCtD
Sunitinib—ABCG2—Doxorubicin—sarcoma	0.00356	0.0428	CbGbCtD
Sunitinib—ABCB1—Dactinomycin—sarcoma	0.00333	0.0401	CbGbCtD
Sunitinib—CYP3A5—Vincristine—sarcoma	0.00315	0.038	CbGbCtD
Sunitinib—ABCB1—Mitoxantrone—sarcoma	0.00298	0.0359	CbGbCtD
Sunitinib—CYP3A5—Etoposide—sarcoma	0.00289	0.0348	CbGbCtD
Sunitinib—ABCB1—Vincristine—sarcoma	0.00205	0.0247	CbGbCtD
Sunitinib—ABCB1—Etoposide—sarcoma	0.00188	0.0226	CbGbCtD
Sunitinib—CYP3A4—Mitoxantrone—sarcoma	0.00179	0.0215	CbGbCtD
Sunitinib—ABCB1—Doxorubicin—sarcoma	0.00128	0.0154	CbGbCtD
Sunitinib—CYP3A4—Vincristine—sarcoma	0.00123	0.0148	CbGbCtD
Sunitinib—CYP3A4—Etoposide—sarcoma	0.00113	0.0136	CbGbCtD
Sunitinib—CYP3A4—Doxorubicin—sarcoma	0.000768	0.00926	CbGbCtD
Sunitinib—STK24—Teniposide—Etoposide—sarcoma	0.000314	0.169	CbGdCrCtD
Sunitinib—CHEK2—Vindesine—Vincristine—sarcoma	0.00014	0.075	CbGdCrCtD
Sunitinib—PLK4—Teniposide—Etoposide—sarcoma	9.99e-05	0.0537	CbGdCrCtD
Sunitinib—CHEK2—Vinorelbine—Vincristine—sarcoma	8.81e-05	0.0473	CbGdCrCtD
Sunitinib—CHEK2—Podofilox—Etoposide—sarcoma	8.81e-05	0.0473	CbGdCrCtD
Sunitinib—CHEK2—Teniposide—Etoposide—sarcoma	8.81e-05	0.0473	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Epirubicin—sarcoma	7.63e-05	0.041	CbGdCrCtD
Sunitinib—DYRK1A—Doxorubicin—Epirubicin—sarcoma	7.63e-05	0.041	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Epirubicin—sarcoma	7.63e-05	0.041	CbGdCrCtD
Sunitinib—DYRK1A—Epirubicin—Doxorubicin—sarcoma	7.06e-05	0.0379	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Doxorubicin—sarcoma	7.06e-05	0.0379	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Doxorubicin—sarcoma	7.06e-05	0.0379	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Epirubicin—sarcoma	6.59e-05	0.0354	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Epirubicin—sarcoma	6.59e-05	0.0354	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Doxorubicin—sarcoma	6.09e-05	0.0327	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Doxorubicin—sarcoma	6.09e-05	0.0327	CbGdCrCtD
Sunitinib—CHEK2—Vinblastine—Vincristine—sarcoma	6.06e-05	0.0326	CbGdCrCtD
Sunitinib—PLK4—Idarubicin—Epirubicin—sarcoma	5.21e-05	0.028	CbGdCrCtD
Sunitinib—PLK4—Doxorubicin—Epirubicin—sarcoma	5.21e-05	0.028	CbGdCrCtD
Sunitinib—PLK4—Idarubicin—Doxorubicin—sarcoma	4.82e-05	0.0259	CbGdCrCtD
Sunitinib—PLK4—Epirubicin—Doxorubicin—sarcoma	4.82e-05	0.0259	CbGdCrCtD
Sunitinib—CHEK2—Doxorubicin—Epirubicin—sarcoma	4.59e-05	0.0247	CbGdCrCtD
Sunitinib—MAP4K4—liver—sarcoma	4.51e-05	0.000616	CbGeAlD
Sunitinib—PRPF4B—lymph node—sarcoma	4.5e-05	0.000614	CbGeAlD
Sunitinib—NUAK2—liver—sarcoma	4.48e-05	0.000611	CbGeAlD
Sunitinib—FLT3—liver—sarcoma	4.45e-05	0.000607	CbGeAlD
Sunitinib—MAP3K12—liver—sarcoma	4.45e-05	0.000607	CbGeAlD
Sunitinib—RPS6KB1—bone marrow—sarcoma	4.44e-05	0.000606	CbGeAlD
Sunitinib—STK39—lymph node—sarcoma	4.44e-05	0.000606	CbGeAlD
Sunitinib—CAMK2G—testis—sarcoma	4.44e-05	0.000606	CbGeAlD
Sunitinib—BMP2K—testis—sarcoma	4.44e-05	0.000606	CbGeAlD
Sunitinib—PDGFRB—hematopoietic system—sarcoma	4.44e-05	0.000605	CbGeAlD
Sunitinib—MAP4K5—lymphoid tissue—sarcoma	4.42e-05	0.000603	CbGeAlD
Sunitinib—FGR—bone marrow—sarcoma	4.41e-05	0.000602	CbGeAlD
Sunitinib—CSF1R—smooth muscle tissue—sarcoma	4.41e-05	0.000601	CbGeAlD
Sunitinib—YES1—cardiac atrium—sarcoma	4.4e-05	0.0006	CbGeAlD
Sunitinib—LRRK2—testis—sarcoma	4.4e-05	0.0006	CbGeAlD
Sunitinib—RPS6KA3—liver—sarcoma	4.39e-05	0.000599	CbGeAlD
Sunitinib—CSNK2A1—lymph node—sarcoma	4.38e-05	0.000598	CbGeAlD
Sunitinib—YES1—uterus—sarcoma	4.38e-05	0.000597	CbGeAlD
Sunitinib—KIT—connective tissue—sarcoma	4.37e-05	0.000597	CbGeAlD
Sunitinib—SLK—tendon—sarcoma	4.37e-05	0.000596	CbGeAlD
Sunitinib—MAP2K1—liver—sarcoma	4.36e-05	0.000595	CbGeAlD
Sunitinib—CSF1R—skin of body—sarcoma	4.35e-05	0.000594	CbGeAlD
Sunitinib—TAOK3—cardiac atrium—sarcoma	4.34e-05	0.000593	CbGeAlD
Sunitinib—STK10—uterus—sarcoma	4.34e-05	0.000592	CbGeAlD
Sunitinib—PRKAA1—testis—sarcoma	4.33e-05	0.000591	CbGeAlD
Sunitinib—MYLK—lymph node—sarcoma	4.32e-05	0.00059	CbGeAlD
Sunitinib—TAOK3—uterus—sarcoma	4.32e-05	0.000589	CbGeAlD
Sunitinib—JAK2—tendon—sarcoma	4.31e-05	0.000588	CbGeAlD
Sunitinib—CSNK1A1—liver—sarcoma	4.3e-05	0.000587	CbGeAlD
Sunitinib—PDGFRA—uterus—sarcoma	4.29e-05	0.000586	CbGeAlD
Sunitinib—PTK2B—testis—sarcoma	4.29e-05	0.000585	CbGeAlD
Sunitinib—CLK1—liver—sarcoma	4.27e-05	0.000583	CbGeAlD
Sunitinib—FLT4—testis—sarcoma	4.27e-05	0.000583	CbGeAlD
Sunitinib—PDGFRB—connective tissue—sarcoma	4.27e-05	0.000583	CbGeAlD
Sunitinib—PLK4—lymph node—sarcoma	4.27e-05	0.000583	CbGeAlD
Sunitinib—FLT1—lymphoid tissue—sarcoma	4.27e-05	0.000583	CbGeAlD
Sunitinib—CHEK2—Epirubicin—Doxorubicin—sarcoma	4.25e-05	0.0228	CbGdCrCtD
Sunitinib—FYN—tendon—sarcoma	4.25e-05	0.00058	CbGeAlD
Sunitinib—STK4—lymph node—sarcoma	4.24e-05	0.000579	CbGeAlD
Sunitinib—SLK—bone marrow—sarcoma	4.23e-05	0.000577	CbGeAlD
Sunitinib—CSNK1E—testis—sarcoma	4.22e-05	0.000575	CbGeAlD
Sunitinib—FGFR1—testis—sarcoma	4.22e-05	0.000575	CbGeAlD
Sunitinib—Toxic epidermal necrolysis—Epirubicin—sarcoma	4.21e-05	0.000593	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Epirubicin—sarcoma	4.21e-05	0.000593	CcSEcCtD
Sunitinib—Hypersensitivity—Thiotepa—sarcoma	4.21e-05	0.000592	CcSEcCtD
Sunitinib—BMP2K—liver—sarcoma	4.2e-05	0.000572	CbGeAlD
Sunitinib—CAMK2G—liver—sarcoma	4.2e-05	0.000572	CbGeAlD
Sunitinib—Nasopharyngitis—Epirubicin—sarcoma	4.18e-05	0.000589	CcSEcCtD
Sunitinib—Face oedema—Doxorubicin—sarcoma	4.18e-05	0.000589	CcSEcCtD
Sunitinib—Hypersensitivity—Dactinomycin—sarcoma	4.17e-05	0.000588	CcSEcCtD
Sunitinib—JAK2—bone marrow—sarcoma	4.17e-05	0.000569	CbGeAlD
Sunitinib—PHKG2—lymph node—sarcoma	4.17e-05	0.000569	CbGeAlD
Sunitinib—LRRK2—liver—sarcoma	4.16e-05	0.000567	CbGeAlD
Sunitinib—MAP3K3—tendon—sarcoma	4.15e-05	0.000566	CbGeAlD
Sunitinib—MAP4K5—tendon—sarcoma	4.15e-05	0.000566	CbGeAlD
Sunitinib—IRAK4—testis—sarcoma	4.15e-05	0.000566	CbGeAlD
Sunitinib—STK24—lymph node—sarcoma	4.15e-05	0.000566	CbGeAlD
Sunitinib—Gastrointestinal pain—Vincristine—sarcoma	4.14e-05	0.000583	CcSEcCtD
Sunitinib—Alanine aminotransferase increased—Epirubicin—sarcoma	4.12e-05	0.000581	CcSEcCtD
Sunitinib—Muscular weakness—Epirubicin—sarcoma	4.12e-05	0.000581	CcSEcCtD
Sunitinib—FYN—bone marrow—sarcoma	4.12e-05	0.000561	CbGeAlD
Sunitinib—DAPK2—lymph node—sarcoma	4.1e-05	0.000559	CbGeAlD
Sunitinib—PRKAA1—liver—sarcoma	4.1e-05	0.000559	CbGeAlD
Sunitinib—Asthenia—Thiotepa—sarcoma	4.1e-05	0.000577	CcSEcCtD
Sunitinib—YES1—lymphoid tissue—sarcoma	4.08e-05	0.000556	CbGeAlD
Sunitinib—Infection—Etoposide—sarcoma	4.07e-05	0.000574	CcSEcCtD
Sunitinib—Abdominal distension—Epirubicin—sarcoma	4.07e-05	0.000573	CcSEcCtD
Sunitinib—Asthenia—Dactinomycin—sarcoma	4.07e-05	0.000573	CcSEcCtD
Sunitinib—MAP2K2—testis—sarcoma	4.06e-05	0.000554	CbGeAlD
Sunitinib—ULK3—testis—sarcoma	4.06e-05	0.000554	CbGeAlD
Sunitinib—Blood creatinine increased—Doxorubicin—sarcoma	4.05e-05	0.000571	CcSEcCtD
Sunitinib—PTK2B—liver—sarcoma	4.05e-05	0.000553	CbGeAlD
Sunitinib—Dysphagia—Epirubicin—sarcoma	4.04e-05	0.000569	CcSEcCtD
Sunitinib—STK10—lymphoid tissue—sarcoma	4.04e-05	0.000551	CbGeAlD
Sunitinib—FLT4—liver—sarcoma	4.04e-05	0.000551	CbGeAlD
Sunitinib—Pruritus—Thiotepa—sarcoma	4.04e-05	0.000569	CcSEcCtD
Sunitinib—STK16—lymph node—sarcoma	4.03e-05	0.00055	CbGeAlD
Sunitinib—Gastrointestinal pain—Mitoxantrone—sarcoma	4.03e-05	0.000568	CcSEcCtD
Sunitinib—MAP3K2—testis—sarcoma	4.03e-05	0.00055	CbGeAlD
Sunitinib—TAOK3—lymphoid tissue—sarcoma	4.03e-05	0.000549	CbGeAlD
Sunitinib—Dehydration—Doxorubicin—sarcoma	4.02e-05	0.000567	CcSEcCtD
Sunitinib—MAP3K3—bone marrow—sarcoma	4.02e-05	0.000549	CbGeAlD
Sunitinib—MAP4K5—bone marrow—sarcoma	4.02e-05	0.000549	CbGeAlD
Sunitinib—Thrombocytopenia—Etoposide—sarcoma	4.02e-05	0.000566	CcSEcCtD
Sunitinib—FLT1—tendon—sarcoma	4.01e-05	0.000548	CbGeAlD
Sunitinib—HIPK2—lymph node—sarcoma	4.01e-05	0.000547	CbGeAlD
Sunitinib—HIPK3—lymph node—sarcoma	4.01e-05	0.000547	CbGeAlD
Sunitinib—ALK—lymph node—sarcoma	4.01e-05	0.000547	CbGeAlD
Sunitinib—Abdominal pain—Vincristine—sarcoma	4e-05	0.000564	CcSEcCtD
Sunitinib—Body temperature increased—Vincristine—sarcoma	4e-05	0.000564	CcSEcCtD
Sunitinib—KIT—smooth muscle tissue—sarcoma	4e-05	0.000546	CbGeAlD
Sunitinib—PDGFRA—lymphoid tissue—sarcoma	4e-05	0.000546	CbGeAlD
Sunitinib—Liver function test abnormal—Doxorubicin—sarcoma	4e-05	0.000563	CcSEcCtD
Sunitinib—MAP3K7—testis—sarcoma	3.99e-05	0.000545	CbGeAlD
Sunitinib—CSNK1E—liver—sarcoma	3.99e-05	0.000544	CbGeAlD
Sunitinib—FGFR1—liver—sarcoma	3.99e-05	0.000544	CbGeAlD
Sunitinib—Skin disorder—Etoposide—sarcoma	3.98e-05	0.000561	CcSEcCtD
Sunitinib—RIOK2—lymph node—sarcoma	3.97e-05	0.000542	CbGeAlD
Sunitinib—TNK1—lymph node—sarcoma	3.97e-05	0.000542	CbGeAlD
Sunitinib—EPHB6—tendon—sarcoma	3.97e-05	0.000541	CbGeAlD
Sunitinib—Dry skin—Doxorubicin—sarcoma	3.97e-05	0.000559	CcSEcCtD
Sunitinib—Pancreatitis—Epirubicin—sarcoma	3.96e-05	0.000558	CcSEcCtD
Sunitinib—Abdominal pain upper—Doxorubicin—sarcoma	3.95e-05	0.000557	CcSEcCtD
Sunitinib—KIT—skin of body—sarcoma	3.95e-05	0.000539	CbGeAlD
Sunitinib—TBK1—testis—sarcoma	3.95e-05	0.000538	CbGeAlD
Sunitinib—Hypokalaemia—Doxorubicin—sarcoma	3.94e-05	0.000555	CcSEcCtD
Sunitinib—MAP4K1—lymph node—sarcoma	3.93e-05	0.000536	CbGeAlD
Sunitinib—IRAK4—liver—sarcoma	3.92e-05	0.000535	CbGeAlD
Sunitinib—TYK2—testis—sarcoma	3.92e-05	0.000535	CbGeAlD
Sunitinib—Anorexia—Etoposide—sarcoma	3.91e-05	0.000551	CcSEcCtD
Sunitinib—PDGFRB—smooth muscle tissue—sarcoma	3.91e-05	0.000533	CbGeAlD
Sunitinib—Diarrhoea—Thiotepa—sarcoma	3.91e-05	0.00055	CcSEcCtD
Sunitinib—Abdominal pain—Mitoxantrone—sarcoma	3.9e-05	0.000549	CcSEcCtD
Sunitinib—Body temperature increased—Mitoxantrone—sarcoma	3.9e-05	0.000549	CcSEcCtD
Sunitinib—Toxic epidermal necrolysis—Doxorubicin—sarcoma	3.9e-05	0.000549	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	3.9e-05	0.000549	CcSEcCtD
Sunitinib—KDR—cardiac atrium—sarcoma	3.89e-05	0.000531	CbGeAlD
Sunitinib—MAP2K5—cardiac atrium—sarcoma	3.89e-05	0.000531	CbGeAlD
Sunitinib—Bronchitis—Epirubicin—sarcoma	3.89e-05	0.000548	CcSEcCtD
Sunitinib—Diarrhoea—Dactinomycin—sarcoma	3.88e-05	0.000546	CcSEcCtD
Sunitinib—KDR—uterus—sarcoma	3.87e-05	0.000528	CbGeAlD
Sunitinib—Nasopharyngitis—Doxorubicin—sarcoma	3.87e-05	0.000545	CcSEcCtD
Sunitinib—IRAK1—testis—sarcoma	3.87e-05	0.000528	CbGeAlD
Sunitinib—PDGFRB—skin of body—sarcoma	3.86e-05	0.000526	CbGeAlD
Sunitinib—DAPK3—lymph node—sarcoma	3.85e-05	0.000526	CbGeAlD
Sunitinib—Pancytopenia—Epirubicin—sarcoma	3.84e-05	0.000541	CcSEcCtD
Sunitinib—ULK3—liver—sarcoma	3.84e-05	0.000524	CbGeAlD
Sunitinib—MAP2K2—liver—sarcoma	3.84e-05	0.000524	CbGeAlD
Sunitinib—YES1—tendon—sarcoma	3.83e-05	0.000523	CbGeAlD
Sunitinib—CLK2—lymph node—sarcoma	3.82e-05	0.000521	CbGeAlD
Sunitinib—Muscular weakness—Doxorubicin—sarcoma	3.82e-05	0.000538	CcSEcCtD
Sunitinib—Alanine aminotransferase increased—Doxorubicin—sarcoma	3.82e-05	0.000538	CcSEcCtD
Sunitinib—MAP3K2—liver—sarcoma	3.81e-05	0.00052	CbGeAlD
Sunitinib—MAP4K2—lymph node—sarcoma	3.8e-05	0.000519	CbGeAlD
Sunitinib—STK10—tendon—sarcoma	3.8e-05	0.000518	CbGeAlD
Sunitinib—CSF1R—cardiac atrium—sarcoma	3.8e-05	0.000518	CbGeAlD
Sunitinib—RPS6KB1—testis—sarcoma	3.8e-05	0.000518	CbGeAlD
Sunitinib—TAOK3—tendon—sarcoma	3.79e-05	0.000516	CbGeAlD
Sunitinib—Neutropenia—Epirubicin—sarcoma	3.78e-05	0.000532	CcSEcCtD
Sunitinib—CSF1R—uterus—sarcoma	3.78e-05	0.000516	CbGeAlD
Sunitinib—Dizziness—Thiotepa—sarcoma	3.78e-05	0.000532	CcSEcCtD
Sunitinib—MAP3K7—liver—sarcoma	3.77e-05	0.000515	CbGeAlD
Sunitinib—RET—testis—sarcoma	3.77e-05	0.000515	CbGeAlD
Sunitinib—FGR—testis—sarcoma	3.77e-05	0.000515	CbGeAlD
Sunitinib—Abdominal distension—Doxorubicin—sarcoma	3.77e-05	0.00053	CcSEcCtD
Sunitinib—PDGFRA—tendon—sarcoma	3.76e-05	0.000513	CbGeAlD
Sunitinib—AXL—testis—sarcoma	3.76e-05	0.000513	CbGeAlD
Sunitinib—Upper respiratory tract infection—Epirubicin—sarcoma	3.76e-05	0.000529	CcSEcCtD
Sunitinib—STK3—lymph node—sarcoma	3.75e-05	0.000512	CbGeAlD
Sunitinib—Dysphagia—Doxorubicin—sarcoma	3.74e-05	0.000527	CcSEcCtD
Sunitinib—TBK1—liver—sarcoma	3.73e-05	0.000509	CbGeAlD
Sunitinib—Hypersensitivity—Vincristine—sarcoma	3.73e-05	0.000525	CcSEcCtD
Sunitinib—YES1—bone marrow—sarcoma	3.71e-05	0.000507	CbGeAlD
Sunitinib—TYK2—liver—sarcoma	3.71e-05	0.000506	CbGeAlD
Sunitinib—Paraesthesia—Etoposide—sarcoma	3.68e-05	0.000519	CcSEcCtD
Sunitinib—STK10—bone marrow—sarcoma	3.68e-05	0.000502	CbGeAlD
Sunitinib—Pancreatitis—Doxorubicin—sarcoma	3.67e-05	0.000517	CcSEcCtD
Sunitinib—TAOK3—bone marrow—sarcoma	3.67e-05	0.0005	CbGeAlD
Sunitinib—IRAK1—liver—sarcoma	3.66e-05	0.000499	CbGeAlD
Sunitinib—Weight decreased—Epirubicin—sarcoma	3.66e-05	0.000515	CcSEcCtD
Sunitinib—Dyspnoea—Etoposide—sarcoma	3.66e-05	0.000515	CcSEcCtD
Sunitinib—Hyperglycaemia—Epirubicin—sarcoma	3.65e-05	0.000514	CcSEcCtD
Sunitinib—Hypersensitivity—Mitoxantrone—sarcoma	3.63e-05	0.000512	CcSEcCtD
Sunitinib—Asthenia—Vincristine—sarcoma	3.63e-05	0.000512	CcSEcCtD
Sunitinib—Vomiting—Thiotepa—sarcoma	3.63e-05	0.000511	CcSEcCtD
Sunitinib—Pneumonia—Epirubicin—sarcoma	3.63e-05	0.000511	CcSEcCtD
Sunitinib—SLK—testis—sarcoma	3.62e-05	0.000494	CbGeAlD
Sunitinib—KDR—lymphoid tissue—sarcoma	3.61e-05	0.000492	CbGeAlD
Sunitinib—DYRK1A—lymph node—sarcoma	3.61e-05	0.000492	CbGeAlD
Sunitinib—Infestation—Epirubicin—sarcoma	3.6e-05	0.000508	CcSEcCtD
Sunitinib—Infestation NOS—Epirubicin—sarcoma	3.6e-05	0.000508	CcSEcCtD
Sunitinib—Vomiting—Dactinomycin—sarcoma	3.6e-05	0.000507	CcSEcCtD
Sunitinib—Rash—Thiotepa—sarcoma	3.6e-05	0.000507	CcSEcCtD
Sunitinib—Bronchitis—Doxorubicin—sarcoma	3.6e-05	0.000507	CcSEcCtD
Sunitinib—Dermatitis—Thiotepa—sarcoma	3.6e-05	0.000507	CcSEcCtD
Sunitinib—RPS6KB1—liver—sarcoma	3.59e-05	0.00049	CbGeAlD
Sunitinib—FGFR2—testis—sarcoma	3.59e-05	0.000489	CbGeAlD
Sunitinib—Headache—Thiotepa—sarcoma	3.58e-05	0.000504	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Epirubicin—sarcoma	3.57e-05	0.000503	CcSEcCtD
Sunitinib—Rash—Dactinomycin—sarcoma	3.57e-05	0.000503	CcSEcCtD
Sunitinib—FGR—liver—sarcoma	3.57e-05	0.000487	CbGeAlD
Sunitinib—JAK2—testis—sarcoma	3.57e-05	0.000487	CbGeAlD
Sunitinib—Decreased appetite—Etoposide—sarcoma	3.56e-05	0.000502	CcSEcCtD
Sunitinib—AXL—liver—sarcoma	3.55e-05	0.000485	CbGeAlD
Sunitinib—Pancytopenia—Doxorubicin—sarcoma	3.55e-05	0.0005	CcSEcCtD
Sunitinib—Renal failure—Epirubicin—sarcoma	3.54e-05	0.000499	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Etoposide—sarcoma	3.54e-05	0.000499	CcSEcCtD
Sunitinib—Asthenia—Mitoxantrone—sarcoma	3.54e-05	0.000498	CcSEcCtD
Sunitinib—Fatigue—Etoposide—sarcoma	3.54e-05	0.000498	CcSEcCtD
Sunitinib—ABCC4—hematopoietic system—sarcoma	3.53e-05	0.000482	CbGeAlD
Sunitinib—Neuropathy peripheral—Epirubicin—sarcoma	3.53e-05	0.000498	CcSEcCtD
Sunitinib—MERTK—lymph node—sarcoma	3.53e-05	0.000481	CbGeAlD
Sunitinib—CSF1R—lymphoid tissue—sarcoma	3.52e-05	0.000481	CbGeAlD
Sunitinib—FYN—testis—sarcoma	3.52e-05	0.00048	CbGeAlD
Sunitinib—Stomatitis—Epirubicin—sarcoma	3.51e-05	0.000495	CcSEcCtD
Sunitinib—Pain—Etoposide—sarcoma	3.51e-05	0.000494	CcSEcCtD
Sunitinib—Constipation—Etoposide—sarcoma	3.51e-05	0.000494	CcSEcCtD
Sunitinib—Urinary tract infection—Epirubicin—sarcoma	3.5e-05	0.000494	CcSEcCtD
Sunitinib—Neutropenia—Doxorubicin—sarcoma	3.5e-05	0.000493	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Doxorubicin—sarcoma	3.48e-05	0.00049	CcSEcCtD
Sunitinib—Diarrhoea—Vincristine—sarcoma	3.46e-05	0.000488	CcSEcCtD
Sunitinib—MAP4K4—lymph node—sarcoma	3.46e-05	0.000472	CbGeAlD
Sunitinib—MAP3K3—testis—sarcoma	3.44e-05	0.000469	CbGeAlD
Sunitinib—MAP4K5—testis—sarcoma	3.44e-05	0.000469	CbGeAlD
Sunitinib—NUAK2—lymph node—sarcoma	3.44e-05	0.000469	CbGeAlD
Sunitinib—KIT—uterus—sarcoma	3.43e-05	0.000468	CbGeAlD
Sunitinib—SLK—liver—sarcoma	3.42e-05	0.000467	CbGeAlD
Sunitinib—MAP3K12—lymph node—sarcoma	3.41e-05	0.000465	CbGeAlD
Sunitinib—FLT3—lymph node—sarcoma	3.41e-05	0.000465	CbGeAlD
Sunitinib—Hepatobiliary disease—Epirubicin—sarcoma	3.41e-05	0.00048	CcSEcCtD
Sunitinib—CYP3A7—liver—sarcoma	3.41e-05	0.000465	CbGeAlD
Sunitinib—Epistaxis—Epirubicin—sarcoma	3.4e-05	0.000479	CcSEcCtD
Sunitinib—KDR—tendon—sarcoma	3.39e-05	0.000463	CbGeAlD
Sunitinib—MAP2K5—tendon—sarcoma	3.39e-05	0.000463	CbGeAlD
Sunitinib—Nausea—Thiotepa—sarcoma	3.39e-05	0.000478	CcSEcCtD
Sunitinib—FGFR2—liver—sarcoma	3.39e-05	0.000463	CbGeAlD
Sunitinib—Weight decreased—Doxorubicin—sarcoma	3.38e-05	0.000477	CcSEcCtD
Sunitinib—Hyperglycaemia—Doxorubicin—sarcoma	3.37e-05	0.000475	CcSEcCtD
Sunitinib—Diarrhoea—Mitoxantrone—sarcoma	3.37e-05	0.000475	CcSEcCtD
Sunitinib—JAK2—liver—sarcoma	3.37e-05	0.00046	CbGeAlD
Sunitinib—PDGFRB—cardiac atrium—sarcoma	3.37e-05	0.00046	CbGeAlD
Sunitinib—Nausea—Dactinomycin—sarcoma	3.37e-05	0.000474	CcSEcCtD
Sunitinib—RPS6KA3—lymph node—sarcoma	3.36e-05	0.000459	CbGeAlD
Sunitinib—Pneumonia—Doxorubicin—sarcoma	3.35e-05	0.000473	CcSEcCtD
Sunitinib—Gastrointestinal pain—Etoposide—sarcoma	3.35e-05	0.000472	CcSEcCtD
Sunitinib—PDGFRB—uterus—sarcoma	3.35e-05	0.000457	CbGeAlD
Sunitinib—Dizziness—Vincristine—sarcoma	3.35e-05	0.000472	CcSEcCtD
Sunitinib—MAP2K1—lymph node—sarcoma	3.34e-05	0.000456	CbGeAlD
Sunitinib—Infestation NOS—Doxorubicin—sarcoma	3.33e-05	0.00047	CcSEcCtD
Sunitinib—Infestation—Doxorubicin—sarcoma	3.33e-05	0.00047	CcSEcCtD
Sunitinib—FYN—liver—sarcoma	3.33e-05	0.000454	CbGeAlD
Sunitinib—FLT1—testis—sarcoma	3.32e-05	0.000453	CbGeAlD
Sunitinib—CSF1R—tendon—sarcoma	3.31e-05	0.000452	CbGeAlD
Sunitinib—Stevens-Johnson syndrome—Doxorubicin—sarcoma	3.31e-05	0.000466	CcSEcCtD
Sunitinib—CSNK1A1—lymph node—sarcoma	3.3e-05	0.00045	CbGeAlD
Sunitinib—Bradycardia—Epirubicin—sarcoma	3.29e-05	0.000464	CcSEcCtD
Sunitinib—KDR—bone marrow—sarcoma	3.29e-05	0.000448	CbGeAlD
Sunitinib—EPHB6—testis—sarcoma	3.29e-05	0.000448	CbGeAlD
Sunitinib—Renal failure—Doxorubicin—sarcoma	3.28e-05	0.000462	CcSEcCtD
Sunitinib—CLK1—lymph node—sarcoma	3.28e-05	0.000447	CbGeAlD
Sunitinib—Neuropathy peripheral—Doxorubicin—sarcoma	3.27e-05	0.00046	CcSEcCtD
Sunitinib—KCNH2—myometrium—sarcoma	3.27e-05	0.000446	CbGeAlD
Sunitinib—Haemoglobin—Epirubicin—sarcoma	3.25e-05	0.000458	CcSEcCtD
Sunitinib—Stomatitis—Doxorubicin—sarcoma	3.25e-05	0.000458	CcSEcCtD
Sunitinib—MAP4K5—liver—sarcoma	3.25e-05	0.000443	CbGeAlD
Sunitinib—MAP3K3—liver—sarcoma	3.25e-05	0.000443	CbGeAlD
Sunitinib—Abdominal pain—Etoposide—sarcoma	3.24e-05	0.000457	CcSEcCtD
Sunitinib—Body temperature increased—Etoposide—sarcoma	3.24e-05	0.000457	CcSEcCtD
Sunitinib—Urinary tract infection—Doxorubicin—sarcoma	3.24e-05	0.000457	CcSEcCtD
Sunitinib—Hepatitis—Epirubicin—sarcoma	3.24e-05	0.000456	CcSEcCtD
Sunitinib—Haemorrhage—Epirubicin—sarcoma	3.24e-05	0.000456	CcSEcCtD
Sunitinib—Hypoaesthesia—Epirubicin—sarcoma	3.22e-05	0.000453	CcSEcCtD
Sunitinib—Vomiting—Vincristine—sarcoma	3.22e-05	0.000453	CcSEcCtD
Sunitinib—CAMK2G—lymph node—sarcoma	3.22e-05	0.000439	CbGeAlD
Sunitinib—BMP2K—lymph node—sarcoma	3.22e-05	0.000439	CbGeAlD
Sunitinib—CSF1R—bone marrow—sarcoma	3.21e-05	0.000438	CbGeAlD
Sunitinib—KIT—lymphoid tissue—sarcoma	3.2e-05	0.000436	CbGeAlD
Sunitinib—Urinary tract disorder—Epirubicin—sarcoma	3.2e-05	0.00045	CcSEcCtD
Sunitinib—Rash—Vincristine—sarcoma	3.19e-05	0.00045	CcSEcCtD
Sunitinib—Dermatitis—Vincristine—sarcoma	3.19e-05	0.000449	CcSEcCtD
Sunitinib—LRRK2—lymph node—sarcoma	3.19e-05	0.000435	CbGeAlD
Sunitinib—Oedema peripheral—Epirubicin—sarcoma	3.19e-05	0.000449	CcSEcCtD
Sunitinib—Connective tissue disorder—Epirubicin—sarcoma	3.18e-05	0.000448	CcSEcCtD
Sunitinib—YES1—testis—sarcoma	3.17e-05	0.000433	CbGeAlD
Sunitinib—Urethral disorder—Epirubicin—sarcoma	3.17e-05	0.000447	CcSEcCtD
Sunitinib—Headache—Vincristine—sarcoma	3.17e-05	0.000447	CcSEcCtD
Sunitinib—Hepatobiliary disease—Doxorubicin—sarcoma	3.15e-05	0.000444	CcSEcCtD
Sunitinib—STK10—testis—sarcoma	3.15e-05	0.000429	CbGeAlD
Sunitinib—Epistaxis—Doxorubicin—sarcoma	3.15e-05	0.000443	CcSEcCtD
Sunitinib—PRKAA1—lymph node—sarcoma	3.14e-05	0.000429	CbGeAlD
Sunitinib—FLT1—liver—sarcoma	3.14e-05	0.000429	CbGeAlD
Sunitinib—Vomiting—Mitoxantrone—sarcoma	3.13e-05	0.000442	CcSEcCtD
Sunitinib—TAOK3—testis—sarcoma	3.13e-05	0.000428	CbGeAlD
Sunitinib—PDGFRB—lymphoid tissue—sarcoma	3.12e-05	0.000426	CbGeAlD
Sunitinib—PDGFRA—testis—sarcoma	3.11e-05	0.000425	CbGeAlD
Sunitinib—Rash—Mitoxantrone—sarcoma	3.11e-05	0.000438	CcSEcCtD
Sunitinib—PTK2B—lymph node—sarcoma	3.11e-05	0.000424	CbGeAlD
Sunitinib—Dermatitis—Mitoxantrone—sarcoma	3.11e-05	0.000437	CcSEcCtD
Sunitinib—FLT4—lymph node—sarcoma	3.1e-05	0.000423	CbGeAlD
Sunitinib—Headache—Mitoxantrone—sarcoma	3.09e-05	0.000435	CcSEcCtD
Sunitinib—Erythema multiforme—Epirubicin—sarcoma	3.06e-05	0.000431	CcSEcCtD
Sunitinib—CSNK1E—lymph node—sarcoma	3.06e-05	0.000417	CbGeAlD
Sunitinib—FGFR1—lymph node—sarcoma	3.06e-05	0.000417	CbGeAlD
Sunitinib—Bradycardia—Doxorubicin—sarcoma	3.05e-05	0.000429	CcSEcCtD
Sunitinib—Eye disorder—Epirubicin—sarcoma	3.02e-05	0.000426	CcSEcCtD
Sunitinib—Hypersensitivity—Etoposide—sarcoma	3.02e-05	0.000426	CcSEcCtD
Sunitinib—IRAK4—lymph node—sarcoma	3.01e-05	0.000411	CbGeAlD
Sunitinib—Haemoglobin—Doxorubicin—sarcoma	3.01e-05	0.000424	CcSEcCtD
Sunitinib—Nausea—Vincristine—sarcoma	3.01e-05	0.000424	CcSEcCtD
Sunitinib—Cardiac disorder—Epirubicin—sarcoma	3e-05	0.000423	CcSEcCtD
Sunitinib—Flushing—Epirubicin—sarcoma	3e-05	0.000423	CcSEcCtD
Sunitinib—YES1—liver—sarcoma	3e-05	0.00041	CbGeAlD
Sunitinib—Haemorrhage—Doxorubicin—sarcoma	2.99e-05	0.000422	CcSEcCtD
Sunitinib—Hepatitis—Doxorubicin—sarcoma	2.99e-05	0.000422	CcSEcCtD
Sunitinib—Hypoaesthesia—Doxorubicin—sarcoma	2.98e-05	0.00042	CcSEcCtD
Sunitinib—STK10—liver—sarcoma	2.97e-05	0.000406	CbGeAlD
Sunitinib—TAOK3—liver—sarcoma	2.96e-05	0.000404	CbGeAlD
Sunitinib—Urinary tract disorder—Doxorubicin—sarcoma	2.96e-05	0.000416	CcSEcCtD
Sunitinib—KCNH2—seminal vesicle—sarcoma	2.95e-05	0.000402	CbGeAlD
Sunitinib—Oedema peripheral—Doxorubicin—sarcoma	2.95e-05	0.000415	CcSEcCtD
Sunitinib—PDGFRA—liver—sarcoma	2.94e-05	0.000402	CbGeAlD
Sunitinib—MAP2K2—lymph node—sarcoma	2.94e-05	0.000401	CbGeAlD
Sunitinib—ULK3—lymph node—sarcoma	2.94e-05	0.000401	CbGeAlD
Sunitinib—Asthenia—Etoposide—sarcoma	2.94e-05	0.000414	CcSEcCtD
Sunitinib—Connective tissue disorder—Doxorubicin—sarcoma	2.94e-05	0.000414	CcSEcCtD
Sunitinib—PDGFRB—tendon—sarcoma	2.94e-05	0.000401	CbGeAlD
Sunitinib—Angiopathy—Epirubicin—sarcoma	2.94e-05	0.000414	CcSEcCtD
Sunitinib—Urethral disorder—Doxorubicin—sarcoma	2.93e-05	0.000413	CcSEcCtD
Sunitinib—Nausea—Mitoxantrone—sarcoma	2.93e-05	0.000413	CcSEcCtD
Sunitinib—Immune system disorder—Epirubicin—sarcoma	2.92e-05	0.000412	CcSEcCtD
Sunitinib—MAP3K2—lymph node—sarcoma	2.92e-05	0.000399	CbGeAlD
Sunitinib—Mediastinal disorder—Epirubicin—sarcoma	2.92e-05	0.000411	CcSEcCtD
Sunitinib—KIT—bone marrow—sarcoma	2.91e-05	0.000397	CbGeAlD
Sunitinib—ABCG2—myometrium—sarcoma	2.9e-05	0.000396	CbGeAlD
Sunitinib—Chills—Epirubicin—sarcoma	2.9e-05	0.000409	CcSEcCtD
Sunitinib—Pruritus—Etoposide—sarcoma	2.9e-05	0.000409	CcSEcCtD
Sunitinib—CYP3A7-CYP3A51P—liver—sarcoma	2.9e-05	0.000395	CbGeAlD
Sunitinib—MAP3K7—lymph node—sarcoma	2.89e-05	0.000395	CbGeAlD
Sunitinib—Arrhythmia—Epirubicin—sarcoma	2.89e-05	0.000407	CcSEcCtD
Sunitinib—TBK1—lymph node—sarcoma	2.86e-05	0.00039	CbGeAlD
Sunitinib—Alopecia—Epirubicin—sarcoma	2.86e-05	0.000403	CcSEcCtD
Sunitinib—PDGFRB—bone marrow—sarcoma	2.84e-05	0.000388	CbGeAlD
Sunitinib—TYK2—lymph node—sarcoma	2.84e-05	0.000388	CbGeAlD
Sunitinib—Mental disorder—Epirubicin—sarcoma	2.83e-05	0.000399	CcSEcCtD
Sunitinib—Erythema multiforme—Doxorubicin—sarcoma	2.83e-05	0.000399	CcSEcCtD
Sunitinib—Malnutrition—Epirubicin—sarcoma	2.82e-05	0.000397	CcSEcCtD
Sunitinib—Erythema—Epirubicin—sarcoma	2.82e-05	0.000397	CcSEcCtD
Sunitinib—MAP2K5—testis—sarcoma	2.81e-05	0.000383	CbGeAlD
Sunitinib—KDR—testis—sarcoma	2.81e-05	0.000383	CbGeAlD
Sunitinib—Diarrhoea—Etoposide—sarcoma	2.81e-05	0.000395	CcSEcCtD
Sunitinib—IRAK1—lymph node—sarcoma	2.8e-05	0.000383	CbGeAlD
Sunitinib—KCNH2—hematopoietic system—sarcoma	2.8e-05	0.000383	CbGeAlD
Sunitinib—Eye disorder—Doxorubicin—sarcoma	2.8e-05	0.000394	CcSEcCtD
Sunitinib—Flushing—Doxorubicin—sarcoma	2.78e-05	0.000391	CcSEcCtD
Sunitinib—Cardiac disorder—Doxorubicin—sarcoma	2.78e-05	0.000391	CcSEcCtD
Sunitinib—Flatulence—Epirubicin—sarcoma	2.78e-05	0.000391	CcSEcCtD
Sunitinib—Dysgeusia—Epirubicin—sarcoma	2.76e-05	0.000389	CcSEcCtD
Sunitinib—RPS6KB1—lymph node—sarcoma	2.75e-05	0.000376	CbGeAlD
Sunitinib—CSF1R—testis—sarcoma	2.74e-05	0.000374	CbGeAlD
Sunitinib—RET—lymph node—sarcoma	2.74e-05	0.000373	CbGeAlD
Sunitinib—FGR—lymph node—sarcoma	2.74e-05	0.000373	CbGeAlD
Sunitinib—Back pain—Epirubicin—sarcoma	2.72e-05	0.000384	CcSEcCtD
Sunitinib—AXL—lymph node—sarcoma	2.72e-05	0.000372	CbGeAlD
Sunitinib—Angiopathy—Doxorubicin—sarcoma	2.72e-05	0.000383	CcSEcCtD
Sunitinib—Dizziness—Etoposide—sarcoma	2.71e-05	0.000382	CcSEcCtD
Sunitinib—Muscle spasms—Epirubicin—sarcoma	2.71e-05	0.000381	CcSEcCtD
Sunitinib—Immune system disorder—Doxorubicin—sarcoma	2.7e-05	0.000381	CcSEcCtD
Sunitinib—Mediastinal disorder—Doxorubicin—sarcoma	2.7e-05	0.00038	CcSEcCtD
Sunitinib—Chills—Doxorubicin—sarcoma	2.69e-05	0.000378	CcSEcCtD
Sunitinib—Arrhythmia—Doxorubicin—sarcoma	2.67e-05	0.000377	CcSEcCtD
Sunitinib—ABCC4—uterus—sarcoma	2.67e-05	0.000364	CbGeAlD
Sunitinib—KDR—liver—sarcoma	2.66e-05	0.000362	CbGeAlD
Sunitinib—MAP2K5—liver—sarcoma	2.66e-05	0.000362	CbGeAlD
Sunitinib—Alopecia—Doxorubicin—sarcoma	2.65e-05	0.000373	CcSEcCtD
Sunitinib—ABCG2—seminal vesicle—sarcoma	2.62e-05	0.000358	CbGeAlD
Sunitinib—Mental disorder—Doxorubicin—sarcoma	2.62e-05	0.000369	CcSEcCtD
Sunitinib—SLK—lymph node—sarcoma	2.62e-05	0.000358	CbGeAlD
Sunitinib—Vomiting—Etoposide—sarcoma	2.61e-05	0.000367	CcSEcCtD
Sunitinib—Erythema—Doxorubicin—sarcoma	2.61e-05	0.000367	CcSEcCtD
Sunitinib—Malnutrition—Doxorubicin—sarcoma	2.61e-05	0.000367	CcSEcCtD
Sunitinib—Anaemia—Epirubicin—sarcoma	2.6e-05	0.000367	CcSEcCtD
Sunitinib—CSF1R—liver—sarcoma	2.59e-05	0.000354	CbGeAlD
Sunitinib—Rash—Etoposide—sarcoma	2.59e-05	0.000364	CcSEcCtD
Sunitinib—JAK2—lymph node—sarcoma	2.59e-05	0.000353	CbGeAlD
Sunitinib—Dermatitis—Etoposide—sarcoma	2.58e-05	0.000364	CcSEcCtD
Sunitinib—Headache—Etoposide—sarcoma	2.57e-05	0.000362	CcSEcCtD
Sunitinib—Flatulence—Doxorubicin—sarcoma	2.57e-05	0.000362	CcSEcCtD
Sunitinib—Dysgeusia—Doxorubicin—sarcoma	2.55e-05	0.00036	CcSEcCtD
Sunitinib—FYN—lymph node—sarcoma	2.55e-05	0.000348	CbGeAlD
Sunitinib—Leukopenia—Epirubicin—sarcoma	2.52e-05	0.000355	CcSEcCtD
Sunitinib—Back pain—Doxorubicin—sarcoma	2.52e-05	0.000355	CcSEcCtD
Sunitinib—Muscle spasms—Doxorubicin—sarcoma	2.51e-05	0.000353	CcSEcCtD
Sunitinib—MAP3K3—lymph node—sarcoma	2.49e-05	0.00034	CbGeAlD
Sunitinib—MAP4K5—lymph node—sarcoma	2.49e-05	0.00034	CbGeAlD
Sunitinib—KIT—testis—sarcoma	2.49e-05	0.00034	CbGeAlD
Sunitinib—Cough—Epirubicin—sarcoma	2.46e-05	0.000346	CcSEcCtD
Sunitinib—Convulsion—Epirubicin—sarcoma	2.44e-05	0.000344	CcSEcCtD
Sunitinib—Nausea—Etoposide—sarcoma	2.44e-05	0.000343	CcSEcCtD
Sunitinib—PDGFRB—testis—sarcoma	2.43e-05	0.000332	CbGeAlD
Sunitinib—Hypertension—Epirubicin—sarcoma	2.43e-05	0.000343	CcSEcCtD
Sunitinib—FLT1—lymph node—sarcoma	2.41e-05	0.000329	CbGeAlD
Sunitinib—Anaemia—Doxorubicin—sarcoma	2.41e-05	0.000339	CcSEcCtD
Sunitinib—Arthralgia—Epirubicin—sarcoma	2.4e-05	0.000338	CcSEcCtD
Sunitinib—Chest pain—Epirubicin—sarcoma	2.4e-05	0.000338	CcSEcCtD
Sunitinib—Myalgia—Epirubicin—sarcoma	2.4e-05	0.000338	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	2.38e-05	0.000335	CcSEcCtD
Sunitinib—EPHB6—lymph node—sarcoma	2.38e-05	0.000325	CbGeAlD
Sunitinib—KIT—liver—sarcoma	2.35e-05	0.000321	CbGeAlD
Sunitinib—Dry mouth—Epirubicin—sarcoma	2.35e-05	0.00033	CcSEcCtD
Sunitinib—ABCC4—tendon—sarcoma	2.34e-05	0.000319	CbGeAlD
Sunitinib—Leukopenia—Doxorubicin—sarcoma	2.33e-05	0.000329	CcSEcCtD
Sunitinib—CYP3A5—hematopoietic system—sarcoma	2.32e-05	0.000316	CbGeAlD
Sunitinib—YES1—lymph node—sarcoma	2.3e-05	0.000314	CbGeAlD
Sunitinib—PDGFRB—liver—sarcoma	2.3e-05	0.000314	CbGeAlD
Sunitinib—Oedema—Epirubicin—sarcoma	2.3e-05	0.000324	CcSEcCtD
Sunitinib—Infection—Epirubicin—sarcoma	2.28e-05	0.000322	CcSEcCtD
Sunitinib—STK10—lymph node—sarcoma	2.28e-05	0.000311	CbGeAlD
Sunitinib—Cough—Doxorubicin—sarcoma	2.27e-05	0.00032	CcSEcCtD
Sunitinib—TAOK3—lymph node—sarcoma	2.27e-05	0.00031	CbGeAlD
Sunitinib—ABCC4—bone marrow—sarcoma	2.27e-05	0.000309	CbGeAlD
Sunitinib—ABCC2—tendon—sarcoma	2.26e-05	0.000309	CbGeAlD
Sunitinib—Shock—Epirubicin—sarcoma	2.26e-05	0.000319	CcSEcCtD
Sunitinib—Convulsion—Doxorubicin—sarcoma	2.26e-05	0.000318	CcSEcCtD
Sunitinib—PDGFRA—lymph node—sarcoma	2.26e-05	0.000308	CbGeAlD
Sunitinib—Nervous system disorder—Epirubicin—sarcoma	2.25e-05	0.000318	CcSEcCtD
Sunitinib—Thrombocytopenia—Epirubicin—sarcoma	2.25e-05	0.000317	CcSEcCtD
Sunitinib—Hypertension—Doxorubicin—sarcoma	2.25e-05	0.000317	CcSEcCtD
Sunitinib—Skin disorder—Epirubicin—sarcoma	2.23e-05	0.000315	CcSEcCtD
Sunitinib—Myalgia—Doxorubicin—sarcoma	2.22e-05	0.000313	CcSEcCtD
Sunitinib—Arthralgia—Doxorubicin—sarcoma	2.22e-05	0.000313	CcSEcCtD
Sunitinib—Chest pain—Doxorubicin—sarcoma	2.22e-05	0.000313	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	2.2e-05	0.00031	CcSEcCtD
Sunitinib—Anorexia—Epirubicin—sarcoma	2.19e-05	0.000309	CcSEcCtD
Sunitinib—Dry mouth—Doxorubicin—sarcoma	2.17e-05	0.000306	CcSEcCtD
Sunitinib—KCNH2—cardiac atrium—sarcoma	2.13e-05	0.00029	CbGeAlD
Sunitinib—Oedema—Doxorubicin—sarcoma	2.13e-05	0.0003	CcSEcCtD
Sunitinib—KCNH2—uterus—sarcoma	2.12e-05	0.000289	CbGeAlD
Sunitinib—Infection—Doxorubicin—sarcoma	2.11e-05	0.000298	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Epirubicin—sarcoma	2.09e-05	0.000295	CcSEcCtD
Sunitinib—Shock—Doxorubicin—sarcoma	2.09e-05	0.000295	CcSEcCtD
Sunitinib—Nervous system disorder—Doxorubicin—sarcoma	2.09e-05	0.000294	CcSEcCtD
Sunitinib—Thrombocytopenia—Doxorubicin—sarcoma	2.08e-05	0.000293	CcSEcCtD
Sunitinib—Insomnia—Epirubicin—sarcoma	2.08e-05	0.000293	CcSEcCtD
Sunitinib—Skin disorder—Doxorubicin—sarcoma	2.07e-05	0.000291	CcSEcCtD
Sunitinib—Paraesthesia—Epirubicin—sarcoma	2.06e-05	0.000291	CcSEcCtD
Sunitinib—Dyspnoea—Epirubicin—sarcoma	2.05e-05	0.000289	CcSEcCtD
Sunitinib—KDR—lymph node—sarcoma	2.04e-05	0.000278	CbGeAlD
Sunitinib—MAP2K5—lymph node—sarcoma	2.04e-05	0.000278	CbGeAlD
Sunitinib—Anorexia—Doxorubicin—sarcoma	2.03e-05	0.000286	CcSEcCtD
Sunitinib—Dyspepsia—Epirubicin—sarcoma	2.02e-05	0.000285	CcSEcCtD
Sunitinib—Decreased appetite—Epirubicin—sarcoma	2e-05	0.000281	CcSEcCtD
Sunitinib—CSF1R—lymph node—sarcoma	1.99e-05	0.000271	CbGeAlD
Sunitinib—Gastrointestinal disorder—Epirubicin—sarcoma	1.98e-05	0.00028	CcSEcCtD
Sunitinib—Fatigue—Epirubicin—sarcoma	1.98e-05	0.000279	CcSEcCtD
Sunitinib—Pain—Epirubicin—sarcoma	1.97e-05	0.000277	CcSEcCtD
Sunitinib—Constipation—Epirubicin—sarcoma	1.97e-05	0.000277	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Doxorubicin—sarcoma	1.94e-05	0.000273	CcSEcCtD
Sunitinib—ABCC4—testis—sarcoma	1.94e-05	0.000264	CbGeAlD
Sunitinib—Insomnia—Doxorubicin—sarcoma	1.92e-05	0.000271	CcSEcCtD
Sunitinib—Paraesthesia—Doxorubicin—sarcoma	1.91e-05	0.000269	CcSEcCtD
Sunitinib—Dyspnoea—Doxorubicin—sarcoma	1.9e-05	0.000267	CcSEcCtD
Sunitinib—ABCG2—uterus—sarcoma	1.88e-05	0.000257	CbGeAlD
Sunitinib—Gastrointestinal pain—Epirubicin—sarcoma	1.88e-05	0.000265	CcSEcCtD
Sunitinib—ABCC2—testis—sarcoma	1.87e-05	0.000256	CbGeAlD
Sunitinib—Dyspepsia—Doxorubicin—sarcoma	1.87e-05	0.000264	CcSEcCtD
Sunitinib—Decreased appetite—Doxorubicin—sarcoma	1.85e-05	0.00026	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Doxorubicin—sarcoma	1.84e-05	0.000259	CcSEcCtD
Sunitinib—Fatigue—Doxorubicin—sarcoma	1.83e-05	0.000258	CcSEcCtD
Sunitinib—ABCC4—liver—sarcoma	1.83e-05	0.00025	CbGeAlD
Sunitinib—Pain—Doxorubicin—sarcoma	1.82e-05	0.000256	CcSEcCtD
Sunitinib—Constipation—Doxorubicin—sarcoma	1.82e-05	0.000256	CcSEcCtD
Sunitinib—Abdominal pain—Epirubicin—sarcoma	1.82e-05	0.000256	CcSEcCtD
Sunitinib—Body temperature increased—Epirubicin—sarcoma	1.82e-05	0.000256	CcSEcCtD
Sunitinib—KIT—lymph node—sarcoma	1.8e-05	0.000246	CbGeAlD
Sunitinib—KCNH2—bone marrow—sarcoma	1.8e-05	0.000245	CbGeAlD
Sunitinib—ABCC2—liver—sarcoma	1.77e-05	0.000242	CbGeAlD
Sunitinib—PDGFRB—lymph node—sarcoma	1.76e-05	0.00024	CbGeAlD
Sunitinib—Gastrointestinal pain—Doxorubicin—sarcoma	1.74e-05	0.000245	CcSEcCtD
Sunitinib—CYP3A4—hematopoietic system—sarcoma	1.74e-05	0.000237	CbGeAlD
Sunitinib—Hypersensitivity—Epirubicin—sarcoma	1.69e-05	0.000239	CcSEcCtD
Sunitinib—Body temperature increased—Doxorubicin—sarcoma	1.68e-05	0.000237	CcSEcCtD
Sunitinib—Abdominal pain—Doxorubicin—sarcoma	1.68e-05	0.000237	CcSEcCtD
Sunitinib—Asthenia—Epirubicin—sarcoma	1.65e-05	0.000232	CcSEcCtD
Sunitinib—Pruritus—Epirubicin—sarcoma	1.63e-05	0.000229	CcSEcCtD
Sunitinib—ABCG2—bone marrow—sarcoma	1.6e-05	0.000218	CbGeAlD
Sunitinib—Diarrhoea—Epirubicin—sarcoma	1.57e-05	0.000222	CcSEcCtD
Sunitinib—Hypersensitivity—Doxorubicin—sarcoma	1.57e-05	0.000221	CcSEcCtD
Sunitinib—KCNH2—testis—sarcoma	1.54e-05	0.00021	CbGeAlD
Sunitinib—Asthenia—Doxorubicin—sarcoma	1.53e-05	0.000215	CcSEcCtD
Sunitinib—Dizziness—Epirubicin—sarcoma	1.52e-05	0.000214	CcSEcCtD
Sunitinib—Pruritus—Doxorubicin—sarcoma	1.5e-05	0.000212	CcSEcCtD
Sunitinib—Vomiting—Epirubicin—sarcoma	1.46e-05	0.000206	CcSEcCtD
Sunitinib—Diarrhoea—Doxorubicin—sarcoma	1.46e-05	0.000205	CcSEcCtD
Sunitinib—Rash—Epirubicin—sarcoma	1.45e-05	0.000204	CcSEcCtD
Sunitinib—Dermatitis—Epirubicin—sarcoma	1.45e-05	0.000204	CcSEcCtD
Sunitinib—Headache—Epirubicin—sarcoma	1.44e-05	0.000203	CcSEcCtD
Sunitinib—ABCB1—myometrium—sarcoma	1.43e-05	0.000195	CbGeAlD
Sunitinib—Dizziness—Doxorubicin—sarcoma	1.41e-05	0.000198	CcSEcCtD
Sunitinib—ABCC4—lymph node—sarcoma	1.4e-05	0.000191	CbGeAlD
Sunitinib—ABCB1—embryo—sarcoma	1.38e-05	0.000188	CbGeAlD
Sunitinib—ABCG2—testis—sarcoma	1.37e-05	0.000186	CbGeAlD
Sunitinib—Nausea—Epirubicin—sarcoma	1.37e-05	0.000192	CcSEcCtD
Sunitinib—ABCC2—lymph node—sarcoma	1.36e-05	0.000185	CbGeAlD
Sunitinib—Vomiting—Doxorubicin—sarcoma	1.35e-05	0.00019	CcSEcCtD
Sunitinib—Rash—Doxorubicin—sarcoma	1.34e-05	0.000189	CcSEcCtD
Sunitinib—Dermatitis—Doxorubicin—sarcoma	1.34e-05	0.000189	CcSEcCtD
Sunitinib—Headache—Doxorubicin—sarcoma	1.33e-05	0.000188	CcSEcCtD
Sunitinib—ABCB1—seminal vesicle—sarcoma	1.29e-05	0.000177	CbGeAlD
Sunitinib—ABCG2—liver—sarcoma	1.29e-05	0.000176	CbGeAlD
Sunitinib—Nausea—Doxorubicin—sarcoma	1.26e-05	0.000178	CcSEcCtD
Sunitinib—ABCB1—hematopoietic system—sarcoma	1.23e-05	0.000168	CbGeAlD
Sunitinib—CYP3A5—liver—sarcoma	1.2e-05	0.000164	CbGeAlD
Sunitinib—KCNH2—lymph node—sarcoma	1.11e-05	0.000152	CbGeAlD
Sunitinib—ABCG2—lymph node—sarcoma	9.91e-06	0.000135	CbGeAlD
Sunitinib—ABCB1—uterus—sarcoma	9.29e-06	0.000127	CbGeAlD
Sunitinib—CYP3A4—liver—sarcoma	9e-06	0.000123	CbGeAlD
Sunitinib—ABCB1—lymphoid tissue—sarcoma	8.66e-06	0.000118	CbGeAlD
Sunitinib—ABCB1—bone marrow—sarcoma	7.88e-06	0.000108	CbGeAlD
Sunitinib—ABCB1—testis—sarcoma	6.74e-06	9.2e-05	CbGeAlD
Sunitinib—ABCB1—liver—sarcoma	6.37e-06	8.69e-05	CbGeAlD
Sunitinib—ABCB1—lymph node—sarcoma	4.89e-06	6.67e-05	CbGeAlD
Sunitinib—PDGFRA—Disease—EGFR—sarcoma	5.92e-07	5.75e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—EGFR—sarcoma	5.92e-07	5.75e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—JUN—sarcoma	5.92e-07	5.75e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—KRAS—sarcoma	5.91e-07	5.74e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IL2—sarcoma	5.9e-07	5.73e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—KRAS—sarcoma	5.9e-07	5.73e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—HRAS—sarcoma	5.89e-07	5.72e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CTNNB1—sarcoma	5.87e-07	5.7e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—SRC—sarcoma	5.87e-07	5.7e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—NRAS—sarcoma	5.85e-07	5.68e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—SRC—sarcoma	5.83e-07	5.67e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IL2—sarcoma	5.83e-07	5.66e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—NRAS—sarcoma	5.81e-07	5.64e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—EGFR—sarcoma	5.8e-07	5.63e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—EGFR—sarcoma	5.8e-07	5.63e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—EGFR—sarcoma	5.79e-07	5.63e-06	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—HRAS—sarcoma	5.78e-07	5.61e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—EGFR—sarcoma	5.78e-07	5.61e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—TP53—sarcoma	5.78e-07	5.61e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—MYC—sarcoma	5.78e-07	5.61e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CCND1—sarcoma	5.76e-07	5.59e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—JUN—sarcoma	5.74e-07	5.58e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IL2—sarcoma	5.73e-07	5.56e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IL2—sarcoma	5.73e-07	5.56e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—KRAS—sarcoma	5.73e-07	5.56e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—TP53—sarcoma	5.72e-07	5.56e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CTNNB1—sarcoma	5.7e-07	5.53e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CCND1—sarcoma	5.68e-07	5.52e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—KRAS—sarcoma	5.68e-07	5.52e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—JUN—sarcoma	5.67e-07	5.51e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—EGFR—sarcoma	5.65e-07	5.48e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—KRAS—sarcoma	5.65e-07	5.48e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—NRAS—sarcoma	5.64e-07	5.48e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CTNNB1—sarcoma	5.63e-07	5.47e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—NRAS—sarcoma	5.61e-07	5.45e-06	CbGpPWpGaD
Sunitinib—TYK2—Immune System—HRAS—sarcoma	5.61e-07	5.45e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—KRAS—sarcoma	5.61e-07	5.44e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MDM2—sarcoma	5.6e-07	5.44e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—SRC—sarcoma	5.6e-07	5.43e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—KRAS—sarcoma	5.59e-07	5.43e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—KRAS—sarcoma	5.59e-07	5.43e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—MYC—sarcoma	5.59e-07	5.43e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CCND1—sarcoma	5.58e-07	5.42e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CCND1—sarcoma	5.58e-07	5.42e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—SRC—sarcoma	5.58e-07	5.41e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—JUN—sarcoma	5.57e-07	5.41e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—JUN—sarcoma	5.57e-07	5.41e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—EGFR—sarcoma	5.57e-07	5.41e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—EGFR—sarcoma	5.54e-07	5.38e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—HRAS—sarcoma	5.54e-07	5.38e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CTNNB1—sarcoma	5.53e-07	5.37e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CTNNB1—sarcoma	5.53e-07	5.37e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—HRAS—sarcoma	5.52e-07	5.36e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—KRAS—sarcoma	5.48e-07	5.32e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—KRAS—sarcoma	5.48e-07	5.32e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—HRAS—sarcoma	5.47e-07	5.32e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—KRAS—sarcoma	5.47e-07	5.31e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—EGFR—sarcoma	5.47e-07	5.31e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MDM2—sarcoma	5.47e-07	5.31e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—KRAS—sarcoma	5.46e-07	5.3e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—MYC—sarcoma	5.45e-07	5.3e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—VEGFA—sarcoma	5.45e-07	5.29e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—HRAS—sarcoma	5.44e-07	5.28e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—HRAS—sarcoma	5.44e-07	5.28e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IL2—sarcoma	5.44e-07	5.28e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IL2—sarcoma	5.42e-07	5.26e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—NRAS—sarcoma	5.38e-07	5.23e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—NRAS—sarcoma	5.36e-07	5.21e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—KRAS—sarcoma	5.34e-07	5.18e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—EGFR—sarcoma	5.33e-07	5.18e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—SRC—sarcoma	5.31e-07	5.15e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CCND1—sarcoma	5.3e-07	5.14e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—EGFR—sarcoma	5.29e-07	5.14e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—JUN—sarcoma	5.29e-07	5.13e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CCND1—sarcoma	5.28e-07	5.13e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—JUN—sarcoma	5.27e-07	5.12e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MDM2—sarcoma	5.27e-07	5.12e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—KRAS—sarcoma	5.26e-07	5.11e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—MYC—sarcoma	5.26e-07	5.1e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CTNNB1—sarcoma	5.25e-07	5.09e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—TP53—sarcoma	5.24e-07	5.09e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MDM2—sarcoma	5.24e-07	5.09e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CTNNB1—sarcoma	5.23e-07	5.08e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—KRAS—sarcoma	5.23e-07	5.08e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—MYC—sarcoma	5.23e-07	5.08e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—HRAS—sarcoma	5.2e-07	5.05e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—HRAS—sarcoma	5.18e-07	5.03e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—VEGFA—sarcoma	5.17e-07	5.02e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—KRAS—sarcoma	5.16e-07	5.01e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—HRAS—sarcoma	5.16e-07	5.01e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—SRC—sarcoma	5.15e-07	5e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—HRAS—sarcoma	5.15e-07	5e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—EGFR—sarcoma	5.14e-07	4.99e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—EGFR—sarcoma	5.11e-07	4.97e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—HRAS—sarcoma	5.11e-07	4.97e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—NRAS—sarcoma	5.11e-07	4.96e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—SRC—sarcoma	5.09e-07	4.94e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TP53—sarcoma	5.05e-07	4.9e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—KRAS—sarcoma	5.04e-07	4.89e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—HRAS—sarcoma	5.02e-07	4.88e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TP53—sarcoma	5.02e-07	4.87e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—VEGFA—sarcoma	5.02e-07	4.87e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—HRAS—sarcoma	5.02e-07	4.87e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—MYC—sarcoma	5.01e-07	4.87e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MDM2—sarcoma	5.01e-07	4.86e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IL2—sarcoma	5e-07	4.86e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—KRAS—sarcoma	5e-07	4.86e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—SRC—sarcoma	5e-07	4.85e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—SRC—sarcoma	5e-07	4.85e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—MYC—sarcoma	5e-07	4.85e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—NRAS—sarcoma	4.96e-07	4.81e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—VEGFA—sarcoma	4.96e-07	4.81e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—EGFR—sarcoma	4.9e-07	4.76e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—NRAS—sarcoma	4.9e-07	4.75e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—EGFR—sarcoma	4.89e-07	4.75e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IL2—sarcoma	4.88e-07	4.74e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CCND1—sarcoma	4.88e-07	4.74e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—JUN—sarcoma	4.87e-07	4.73e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—HRAS—sarcoma	4.87e-07	4.73e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—VEGFA—sarcoma	4.87e-07	4.73e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—VEGFA—sarcoma	4.87e-07	4.73e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TP53—sarcoma	4.87e-07	4.73e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TP53—sarcoma	4.87e-07	4.73e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—KRAS—sarcoma	4.86e-07	4.72e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CTNNB1—sarcoma	4.83e-07	4.69e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—HRAS—sarcoma	4.83e-07	4.69e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—KRAS—sarcoma	4.83e-07	4.69e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—NRAS—sarcoma	4.81e-07	4.67e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—NRAS—sarcoma	4.81e-07	4.67e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—HRAS—sarcoma	4.8e-07	4.66e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—HRAS—sarcoma	4.77e-07	4.63e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CCND1—sarcoma	4.76e-07	4.62e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MYC—sarcoma	4.76e-07	4.62e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—HRAS—sarcoma	4.75e-07	4.62e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—HRAS—sarcoma	4.75e-07	4.62e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—JUN—sarcoma	4.75e-07	4.61e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TP53—sarcoma	4.74e-07	4.61e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—SRC—sarcoma	4.74e-07	4.6e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—SRC—sarcoma	4.73e-07	4.59e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CTNNB1—sarcoma	4.71e-07	4.58e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IL2—sarcoma	4.71e-07	4.57e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ENO2—sarcoma	4.69e-07	4.55e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL2—sarcoma	4.68e-07	4.55e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—HBA1—sarcoma	4.66e-07	4.52e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—HRAS—sarcoma	4.65e-07	4.52e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—HRAS—sarcoma	4.65e-07	4.52e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—HRAS—sarcoma	4.65e-07	4.52e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—EGFR—sarcoma	4.65e-07	4.52e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—HRAS—sarcoma	4.64e-07	4.5e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—KRAS—sarcoma	4.63e-07	4.5e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—VEGFA—sarcoma	4.62e-07	4.49e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MYC—sarcoma	4.62e-07	4.48e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—KRAS—sarcoma	4.62e-07	4.48e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—VEGFA—sarcoma	4.61e-07	4.47e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CCND1—sarcoma	4.59e-07	4.46e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—JUN—sarcoma	4.58e-07	4.45e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CCND1—sarcoma	4.56e-07	4.43e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—NRAS—sarcoma	4.56e-07	4.43e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MYC—sarcoma	4.56e-07	4.43e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—JUN—sarcoma	4.55e-07	4.42e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—NRAS—sarcoma	4.55e-07	4.42e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CTNNB1—sarcoma	4.54e-07	4.41e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—HRAS—sarcoma	4.54e-07	4.4e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CTNNB1—sarcoma	4.52e-07	4.39e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EGFR—sarcoma	4.52e-07	4.38e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MYC—sarcoma	4.48e-07	4.35e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MYC—sarcoma	4.48e-07	4.35e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL2—sarcoma	4.47e-07	4.35e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—HRAS—sarcoma	4.47e-07	4.34e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EGFR—sarcoma	4.46e-07	4.33e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—HRAS—sarcoma	4.45e-07	4.32e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KRAS—sarcoma	4.39e-07	4.27e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—HRAS—sarcoma	4.39e-07	4.26e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EGFR—sarcoma	4.38e-07	4.25e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EGFR—sarcoma	4.38e-07	4.25e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—SRC—sarcoma	4.37e-07	4.24e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCND1—sarcoma	4.36e-07	4.24e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—JUN—sarcoma	4.35e-07	4.23e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CTNNB1—sarcoma	4.32e-07	4.19e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—HRAS—sarcoma	4.28e-07	4.16e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KRAS—sarcoma	4.27e-07	4.14e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—SRC—sarcoma	4.26e-07	4.14e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—VEGFA—sarcoma	4.25e-07	4.13e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—HRAS—sarcoma	4.25e-07	4.13e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MYC—sarcoma	4.25e-07	4.13e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MYC—sarcoma	4.24e-07	4.12e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KRAS—sarcoma	4.21e-07	4.09e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—NRAS—sarcoma	4.2e-07	4.08e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EGFR—sarcoma	4.16e-07	4.04e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—VEGFA—sarcoma	4.15e-07	4.03e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EGFR—sarcoma	4.15e-07	4.03e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KRAS—sarcoma	4.14e-07	4.02e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—KRAS—sarcoma	4.14e-07	4.02e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—HRAS—sarcoma	4.13e-07	4.01e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—sarcoma	4.12e-07	4e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—SRC—sarcoma	4.11e-07	3.99e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—HRAS—sarcoma	4.11e-07	3.99e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—NRAS—sarcoma	4.1e-07	3.98e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—SRC—sarcoma	4.09e-07	3.97e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—VEGFA—sarcoma	4e-07	3.88e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—VEGFA—sarcoma	3.98e-07	3.86e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PLCG1—sarcoma	3.98e-07	3.86e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NRAS—sarcoma	3.95e-07	3.84e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—HRAS—sarcoma	3.94e-07	3.82e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NRAS—sarcoma	3.93e-07	3.82e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KRAS—sarcoma	3.93e-07	3.81e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—HRAS—sarcoma	3.92e-07	3.81e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KRAS—sarcoma	3.92e-07	3.8e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MYC—sarcoma	3.91e-07	3.8e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—sarcoma	3.91e-07	3.79e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—SRC—sarcoma	3.9e-07	3.79e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EGFR—sarcoma	3.83e-07	3.72e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MYC—sarcoma	3.82e-07	3.71e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—VEGFA—sarcoma	3.8e-07	3.69e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—sarcoma	3.79e-07	3.68e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NRAS—sarcoma	3.76e-07	3.65e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—sarcoma	3.74e-07	3.64e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EGFR—sarcoma	3.74e-07	3.63e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—HRAS—sarcoma	3.74e-07	3.63e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MYC—sarcoma	3.68e-07	3.57e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—sarcoma	3.68e-07	3.57e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—sarcoma	3.68e-07	3.57e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MYC—sarcoma	3.66e-07	3.56e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—HRAS—sarcoma	3.63e-07	3.52e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KRAS—sarcoma	3.62e-07	3.51e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EGFR—sarcoma	3.6e-07	3.5e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EGFR—sarcoma	3.58e-07	3.48e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—HRAS—sarcoma	3.58e-07	3.48e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KRAS—sarcoma	3.53e-07	3.43e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HRAS—sarcoma	3.52e-07	3.42e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HRAS—sarcoma	3.52e-07	3.42e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MYC—sarcoma	3.5e-07	3.4e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—sarcoma	3.49e-07	3.39e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—sarcoma	3.48e-07	3.38e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EGFR—sarcoma	3.42e-07	3.32e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KRAS—sarcoma	3.4e-07	3.3e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KRAS—sarcoma	3.38e-07	3.28e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HRAS—sarcoma	3.34e-07	3.24e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HRAS—sarcoma	3.33e-07	3.23e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KRAS—sarcoma	3.23e-07	3.14e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—sarcoma	3.21e-07	3.12e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—sarcoma	3.14e-07	3.05e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HRAS—sarcoma	3.07e-07	2.98e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—sarcoma	3.02e-07	2.94e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—sarcoma	3.01e-07	2.92e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HRAS—sarcoma	3e-07	2.91e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HRAS—sarcoma	2.89e-07	2.81e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HRAS—sarcoma	2.88e-07	2.79e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—sarcoma	2.87e-07	2.79e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HRAS—sarcoma	2.75e-07	2.67e-06	CbGpPWpGaD
